Benign Essential Blepharospasm (BEB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Benign Essential Blepharospasm (BEB) is a rare neurological condition that causes involuntary muscle spasms and contractions in the facial muscles around the eyes. Symptoms vary from mild, occasional eyelid twitching to frequent blinking and, in severe cases, continuous spasms leading to functional blindness. The cause is unclear but is thought to be localized dystonia. During spasms, patients with BEB may experience tearing, eye irritation, light sensitivity, and vague eye pain. It typically begins with intermittent forced blinking and eye irritation, often triggered by bright lights, stress, fatigue, or pollution. Unlike hemifacial spasms, BEB affects both eyes. Symptoms usually occur while awake and subside during sleep. Some relief can be found through sleep, relaxation, looking down, using artificial tears, talking, eyelid traction, singing, or humming. While there's no cure, treatment options include managing triggers, wearing tinted sunglasses, maintaining good lid hygiene, and addressing dry eyes. The prognosis varies from mild to severe.

·       Approximately 2,000 new BEB cases are diagnosed annually in the United States, with a prevalence of about 5 in 100,000 people. It primarily affects females, with a female-to-male ratio of 1.8:1, and typically begins around age 56, most commonly in those over 60.

 

Thelansis’s “Benign Essential Blepharospasm (BEB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Benign Essential Blepharospasm (BEB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Benign Essential Blepharospasm (BEB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Benign Essential Blepharospasm (BEB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Benign Essential Blepharospasm (BEB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Benign Essential Blepharospasm (BEB), Benign Essential Blepharospasm (BEB) market outlook, Benign Essential Blepharospasm (BEB) competitive landscape, Benign Essential Blepharospasm (BEB) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)